Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 133 от 154

Активно (без набиране) Фаза 4

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of ARPI therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and ARPI therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer. Participants in this study will receive either Radium-223 dichloride or a ARPI therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral ARPI therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain.

Начало: 09.11.2020 Край: 12.10.2026 Възраст: от 18 г. Лечение

Australia, Czechia, Finland +15 Bayer NCT04597125

Активно (без набиране) Фаза 3

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.

Начало: 05.11.2020 Край: 15.04.2039 Възраст: 4–7 г. Лечение

Australia, Belgium, Canada +12 Pfizer NCT04281485

Активно (без набиране) Фаза 1/2

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Diffuse Large B-Cell Lymphoma Follicular Lymphoma

The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The treatment duration for each participant depends upon which arm of treatment they are assigned to. * The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks. * All participants will receive active drug; no one will be given placebo. Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned. Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.

Начало: 03.11.2020 Край: 30.09.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Czechia +10 Genmab NCT04663347

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

AL Amyloidosis

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.

Начало: 03.11.2020 Край: 08.04.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +15 Alexion Pharmaceuticals, Inc. NCT04512235

Активно (без набиране)

Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD

Pulmonary Fibrosis

The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation between the most prevalent fibrotic interstitial lung diseases. The value of eNose as biomarker for disease progression and response to treatment is also assessed. Besides, validity of several questionnaires for pulmonary fibrosis is investigated.

Начало: 01.11.2020 Край: 31.12.2026

Australia, France, Germany +2 Erasmus Medical Center NCT04680832

Активно (без набиране) Фаза 2

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Melanoma

The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

Начало: 30.10.2020 Край: 02.02.2027 Възраст: 12–120 г. Лечение

Argentina, Australia, Belgium +9 Novartis Pharmaceuticals NCT04417621

Активно (без набиране) Фаза 3

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder Cancer High-grade Ta/ T1 Papillary Disease Bladder Cancer

This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC

Начало: 27.10.2020 Край: 24.12.2031 Възраст: от 18 г. Лечение

Australia, Canada, Japan +3 CG Oncology, Inc. NCT04452591

Активно (без набиране) Фаза 2

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Merkel Cell Carcinoma Merkel Cell Carcinoma, Stage I Merkel Cell Carcinoma, Stage II Merkel Cell Carcinoma, Stage III +2

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

Начало: 26.10.2020 Край: 30.04.2030 Възраст: от 18 г. Лечение

Australia, New Zealand Melanoma and Skin Cancer Trials Limited NCT04291885

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

Начало: 26.10.2020 Край: 21.07.2027 Възраст: 18–65 г. Лечение

Argentina, Australia, Brazil +22 Hoffmann-La Roche NCT04544449

Активно (без набиране) Фаза 3

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

This is a multicenter, randomized, double-blind, placebo-controlled study of niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have achieved stable disease (SD), partial response (PR), or complete response (CR) following completion of standard of care first-line (SoC 1L) platinum-based induction chemotherapy with pembrolizumab. The primary hypotheses are: participants with confirmed diagnosis of NSCLC could benefit from niraparib plus pembrolizumab versus placebo plus pembrolizumab with respect to Progression-free survival (PFS) and Overall survival (OS).

Начало: 26.10.2020 Край: 06.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +23 GlaxoSmithKline NCT04475939

Активно (без набиране) Фаза 3

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Cancer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.

Начало: 20.10.2020 Край: 26.06.2028 Възраст: от 18 г. Друго

Argentina, Australia, Belarus +33 Bayer NCT04464226

Активно (без набиране) Фаза 3

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Metastatic Prostate Cancer Prostate Adenocarcinoma

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Начало: 19.10.2020 Край: 16.10.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Exelixis NCT04446117

Активно (без набиране)

CHAMPION-AF Clinical Trial

Atrial Fibrillation Stroke Bleeding

The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.

Начало: 15.10.2020 Край: 01.12.2027 Възраст: от 18 г. Превенция

Australia, Belgium, Canada +12 Boston Scientific Corporation NCT04394546

Активно (без набиране)

Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea (DREAM)

Obstructive Sleep Apnea

A multicenter study to assess the safety and effectiveness of the Genio dual-sided hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in adults subjects.

Начало: 14.10.2020 Край: 01.02.2028 Възраст: 22–75 г. Лечение

Australia, Belgium, Germany +1 Nyxoah S.A. NCT03868618

Активно (без набиране) Фаза 2

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Acute Leukemia Myelodysplasia Chronic Graft-versus-host-disease

A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.

Начало: 14.10.2020 Край: 07.02.2026 Възраст: 16–70 г. Превенция

Australia, Canada McMaster University NCT04202835

Активно (без набиране) Фаза 3

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Carcinoma, Non-Small-Cell Lung

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

Начало: 13.10.2020 Край: 02.08.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +22 Janssen Research & Development, LLC NCT04538664

Активно (без набиране) Фаза 2

A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

Achondroplasia

Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery

Начало: 10.10.2020 Край: 01.12.2027 Възраст: до 12 г. Лечение

Australia, United Kingdom BioMarin Pharmaceutical NCT04554940

Активно (без набиране) Фаза 3

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

Начало: 09.10.2020 Край: 25.03.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Hoffmann-La Roche NCT04546009

Активно (без набиране) Фаза 1/2

Targeted Therapy and Avelumab in Merkel Cell Carcinoma

Metastatic Merkel Cell Carcinoma

10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor radionuclide therapy; PRRT) or external beam radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).

Начало: 08.10.2020 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia Melanoma and Skin Cancer Trials Limited NCT04261855

Активно (без набиране) Фаза 3

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Diffuse Large B-Cell Lymphoma

Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.

Начало: 08.10.2020 Край: 22.02.2027 Възраст: 18–75 г. Лечение

Australia, Belgium, Brazil +18 Acerta Pharma BV NCT04529772

1 … 131 132 133 134 135 … 154